Stocks Health care AIM
NYSE · Health careAIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. brought in $95K of revenue over the twelve months to June 30, 2026, down 21.5% from a year earlier. It posted a net loss of $14.3M. At June 30, 2026 it held $9.9M in cash against $3.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about AIM ImmunoTech Inc.
- Net worth
- AIM ImmunoTech Inc. has a market value (market cap) of $4.5M at the latest share price, and shareholders' equity of $7.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $88K (-48.2% year on year), with a net loss of $14M. Over the 12 months to June 30, 2026: revenue $95K, net loss $14.3M.
- Cash flow
- In fiscal 2025 operations used $11M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What AIM ImmunoTech Inc. does
AIM ImmunoTech Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker AIM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $88K | -$14M | -$8.62 | n/a |
| 2024 | $170K | -$17.3M | -$30.92 | -$14.9M |
| 2023 | $202K | -$29M | -$59.85 | n/a |
| 2022 | $141K | -$19.4M | -$39.90 | -$16.2M |
| 2021 | $135K | -$19.1M | -$39.90 | -$14M |
| 2020 | $163K | -$14.4M | -$44.88 | -$10.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AIM ranks in Health care
Latest SEC filings
What AIM ImmunoTech Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026
- September 30, 2026Proxy statement DEF 14A
- September 14, 2026
- September 10, 2026
- September 4, 2026
- August 11, 2026
- August 10, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 4% to $26K versus the same quarter last year; diluted EPS -$0.43 versus -$3.68.
- August 6, 2026
- August 5, 2026
Insider trades
What the people running AIM ImmunoTech Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $13.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Equels Thomas KCEO & President, Director | Bought | 24,000 | $5K |
| September 16, 2026 | Equels Thomas KCEO & President, Director | Bought | 11,000 | $2.3K |
| September 15, 2026 | Equels Thomas KCEO & President, Director | Bought | 22,000 | $4.9K |
| September 14, 2026 | Equels Thomas KCEO & President, Director | Bought | 5,900 | $1.3K |
| March 12, 2026 | Chemerow David I.Director | Exercised options | 25,000 | - |
| March 12, 2026 | Equels Thomas KCEO & President, Director | Exercised options | 25,000 | - |
| February 5, 2026 | Chemerow David I.Director | Received as payindirect | 2,800 | $3.4K |
Who owns AIM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orca Capital AG13G, passive | 9.9% | May 12, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 222,626 shares in total, about $32.9K at the last price.
| Holder | Shares |
|---|---|
| Equels Thomas KCEO & President, Director | 190,744 |
| Chemerow David I.Director | 31,8823,441 held indirectly |
Questions about AIM
What does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc. is a company in the Health care sector, listed on NYSE as AIM. Its shares trade on NYSE under the ticker AIM.
What is AIM ImmunoTech Inc.'s net worth?
AIM ImmunoTech Inc. has a market value (market cap) of $4.5M at the latest share price, and shareholders' equity of $7.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AIM ImmunoTech Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.3M on revenue of $95K.
How much revenue does AIM ImmunoTech Inc. make?
Over the twelve months to June 30, 2026 AIM ImmunoTech Inc. reported revenue of $95K. That is 21.5% less than a year earlier.
When did AIM ImmunoTech Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from September 30, 2026.
Similar companies
Compare AIM with
Follow AIM
Get an email when AIM ImmunoTech Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AIM ImmunoTech Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.